Literature DB >> 16496230

Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.

Cynthia Levy1, Keith D Lindor.   

Abstract

Primary sclerosing cholangitis is a progressive disease associated with significant morbidity and mortality that continues to draw attention from investigators worldwide. Epidemiologic studies indicate that its annual incidence remains stable, although more asymptomatic cases are being diagnosed. Nevertheless, even asymptomatic cases can progress to end-stage liver disease, albeit at a highly variable rate. Moreover, patients are predisposed to several malignancies, especially cholangiocarcinoma, which contributes to their decreased survival. On the other hand, a subgroup of patients with the so-called small-duct variant may have a better prognosis, and those with overlap syndromes with autoimmune hepatitis may respond well to immunosuppressants. Otherwise, efficient treatment is not available for patients with primary sclerosing cholangitis. Thus, even though it occurs rarely, this disease is commonly an indication for liver transplantation. Fortunately, transplantation outcomes are excellent, with overall 5-year survival rates of approximately 80%.

Entities:  

Mesh:

Year:  2006        PMID: 16496230     DOI: 10.1055/s-2006-933560

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  18 in total

Review 1.  Primary sclerosing cholangitis--approach to diagnosis.

Authors:  Ian L Steele; Cynthia Levy; Keith D Lindor
Journal:  MedGenMed       Date:  2007-04-25

Review 2.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

3.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

4.  Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature.

Authors:  A K Singal; C M Stanca; V Clark; L Dixon; C Levy; J A Odin; M I Fiel; S L Friedman; N Bach
Journal:  Hepatol Int       Date:  2011-03-11       Impact factor: 6.047

Review 5.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

6.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

Review 7.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

8.  Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.

Authors:  David S Goldberg; Amanda Camp; Alvaro Martinez-Camacho; Lisa Forman; Brett Fortune; K Rajender Reddy
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

Review 9.  The medical management of primary sclerosing cholangitis.

Authors:  Anthony Michaels; Cynthia Levy
Journal:  Medscape J Med       Date:  2008-03-12

10.  Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.

Authors:  James H Tabibian; Andrea Gossard; Mounif El-Youssef; John E Eaton; Jan Petz; Roberta Jorgensen; Felicity B Enders; Anilga Tabibian; Keith D Lindor
Journal:  Am J Ther       Date:  2017 Jan/Feb       Impact factor: 2.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.